ViGenCell Inc. specializes in immune cell therapy. It develops ViTier, a T-cell therapy platform that uses antigen-specific killer T cells to target and remove cancer cells; ViRanger, a T-cell gene therapy platform that uses innate killer T cells to target and eliminate abnormal cells; and ViMedier, an immunosuppressive cell therapy platform that uses the differentiation and expansion of cord blood derived myeloid suppressor cells for universal use. The company was founded in 1995 and is based in Seoul, South Korea.
Stock data | 2024 | Change |
---|---|---|
Price | $2.78 | N/A |
Market Cap | $53.01M | N/A |
Shares Outstanding | 19.08M | N/A |
Employees | 74.00 | N/A |